Rhythm Biosciences (ASX:RHY) welcomes new CEO

Rhythm Biosciences appointed David Atkins as CEO, effective May 13.

Atkins brings extensive healthcare leadership experience and a strong background in life sciences to drive the company's mission forward, particularly in developing an early detection test for colorectal cancer.

The appointment follows a thorough search process led by the company's board and recruitment agencies.